SANTA CLARA, Calif., Aug. 30, 2018 -- Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, "Conquering Aging: Novel Technology Disruptions in the Anti-aging Industry", on Tuesday, September 18, 2018, from 11:00 AM to 12:00 PM Eastern Time. The webinar will offer expert insight from Neelotpal Goswami, Life Sciences Senior Industry Analyst and Unmesh Lal, Life Sciences Program Manager, both from the Transformational Health Practice at Frost & Sullivan; Alex Zhavoronkov, Founder and CEO, Insilico Medicine; Frank Jaksch, Co-Founder & Executive Chairman, ChromaDex; and Edward Cox, CEO, Dthera Sciences.
As the global population rapidly ages, it is creating immense pressure on healthcare systems across countries and regions. The improvement in life expectancy levels has created a large cohort of aged patients who suffer from one or more chronic diseases. Traditionally, the approach towards the management of such aging-related issues has been focused on "repair", i.e. treatment of the various age-related ailments. However, the industry's approach has gradually changed—with growing focus on prevention and management of such symptoms.
"The industry's movement towards a "prevent-manage-repair" continuum is creating opportunities for integrative approaches for age management. For instance, consumers are showing interest in dietary supplements with clinical promise such as Nicotinamide Riboside, Coenzyme Q-10 and herbal extracts such as curcumin," observed Goswami.
The "prevent-manage-repair" continuum is creating novel market opportunities for integrative approaches including aesthetics procedures, alternative therapies, and digital tools. Those approaches combined with advanced clinical therapeutics such as regenerative medicine as well as pharmacological targeting of aging (focused on telomeres, rapalogs, senescent cell targeting, mitochondria-based therapies, etc.) are key opportunities in this space.
"Digital pills that can track medication consumption will improve drug adherence, a key challenge in the treatment of the elderly population. The 'drug-as-a-service' model will impact the anti-aging space with the advent of digital therapeutics that amalgamates mobile technology with artificial intelligence (AI) and big-data analytics. This will drive technology collaborations between drug and technology companies aimed at improving drug efficacy and adherence," concluded Lal.
The informative webinar will cover key insights:
SOURCE Frost & Sullivan